

Perdus de vue – point sur les réflexions et perspectives

Dr Alain Akondé, Grégoire Lurton, Nathalie Daries,
Dr Alamako Doumbia, Dr Drissa Katile, Dr Louis Pizarro

Historique de la PEC à Ségou

2003 à 2005 (initiation)

3 sites à Ségou ville

2006 à 2007 (décentralisation)

- **2006 (2 sites)**

- **2007 (5 sites)**

2008 à 2009 (consolidation =
renforcement des capacités et des
compétences)

Au total = 19 sites (dont 9 affiliés)



1171 patients sous traitement mi 2009

Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007–2009: systematic review

Matthew P. Fox^{1,2,3} and Sydney Rosen^{1,2,3}

¹ Center for Global Health and Development, Boston University, Boston MA, USA

² Health Economics and Epidemiology Research Office, Wits Health Consortium, Johannesburg, South Africa

³ Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Table 2 Rates of Patient Attrition and Retention from Antiretroviral Treatment Programs in Sub-Saharan Africa, as reported

Study Code	Median follow-up (months)	Died (A)	Lost to follow-up (B)	Total attrition from ART (C)*	Total retained (D)*	Transferred care (E)	Total retained at original site (F)*
Botswana 1 †	10.1	16.8%	5.4%	22.2%	77.8%	0.0%	77.8%
Botswana 2	41.9	19.0%	16.1%	35.1%	64.9%	19.1%	45.8%
Weighted averages ‡‡	26.3	9.1%	13.0%	22.1%	77.9%	1.1%	76.8%

“—” indicates that these data could not be determined from the report.

*Calculations: C = A+B; D = 1 - C; F = D-E.

†Rates are based on results after active tracing of patients.

‡Median not reported but estimated as last time period reported to as >50% of cohort was still retained.

§Median not reported; weighted mean for those lost and those retained by sample size.

¶Median not reported; table shows mean follow-up instead.

**Not reported but > 6 months.

††Estimated from KM curve.

‡‡Weighted by cohort size.

Table 3 Retention of Patients at 6, 12, 18, 24 and 36 months after initiation of antiretroviral therapy in sub-Saharan Africa

Study code	Percentage of patients retained at month					Notes
	6	12	18	24	36	
Botswana 1	-	77.8%	-	-	-	12 month value is at a median of 10.1 months
Botswana 2	-	73.8%	-	-	63.9%	Values estimated from KM estimates of LTFU and death
Cameroon 1	-	65.0%	-	-	-	Values estimated from KM curves counting LTFU as an event
(. . .)						
Uganda 4	91.0%	-	-	-	-	6 month estimate at 8.3 months
Zambia 1	-	73.2%	-	-	-	
Simple averages	85.6%	78.3%	78.6%	75.4%	71.9%	

KM, Kaplan-Meier.


Evolution du taux de perdus de vue en Afrique sub-Saharienne

Article	Rosen, Fox & Gill (2007)	Fox & Rosen (2010)
Rétention à M6	79,1	86,1 %
Rétention à M12	75,0 %	80,2 %
Rétention à M24	61,6 %	76,8 %

Rosen S, Fox MP & Gill CJ (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. *PLoS Medicine*

- Amélioration du suivi
- Biais de publication?

Attrition dans le programme TB au Mali



Source : OMS 2010

Comment regarder les PDV ?

- 3 étapes
 - Définition
 - Mesure
 - Explication
- 2 perspectives
 - Suivi individuel
 - Suivi-évaluation des programmes

DÉFINITION

Table 1. Performance of Various Time Intervals After a Missed Appointment in Defining Loss to Follow-up Among Patients Enrolled in a Multisite Human Immunodeficiency Virus Treatment Cohort Between April 1, 2004, and December 31, 2007, Lusaka, Zambia

LTFU Threshold ^a , days	No. Classified as LTFU	No. Who Subsequently Returned to Care	Sensitivity, %	Specificity, %	Misclassification, %
≥ 7	9,269	3,308	92.6	87.9	11.2
≥ 14	8,397	2,539	91.0	90.7	9.3
≥ 21	7,686	1,907	89.8	93.0	7.6
≥ 28	7,063	1,377	88.3	95.0	6.3
≥ 35	6,730	1,110	87.3	95.9	5.7
≥ 42	6,499	938	86.4	96.6	5.4
≥ 49	6,295	798	85.4	97.1	5.2
≥ 56 ^b	6,104	688	84.1	97.5	5.1
≥ 63	5,958	617	83.0	97.7	5.1
≥ 70	5,841	576	82.8	97.9	5.2
≥ 77	5,714	528	80.6	98.1	5.3
≥ 84	5,603	493	79.4	98.2	5.4
≥ 91	5,514	462	78.5	98.3	5.5
≥ 98	5,431	441	77.5	98.4	5.6
≥ 105	5,333	421	76.3	98.5	5.8
≥ 112	5,235	403	75.1	98.5	6.0
≥ 119	5,147	383	74.0	98.6	6.1
≥ 126	5,073	371	73.1	98.6	6.3
≥ 133	4,991	356	72.0	98.7	6.4
≥ 140	4,910	344	70.9	98.7	6.6
≥ 147	4,837	329	70.0	98.8	6.7
≥ 154	4,780	317	69.3	98.8	6.8
≥ 161	4,724	309	68.6	98.9	6.9
≥ 168	4,656	297	67.7	98.9	7.1
≥ 175	4,581	286	66.7	99.0	7.2
≥ 182	4,511	275	65.8	99.0	7.4

Abbreviation: LTFU, loss to follow-up.


^a For illustrative purposes, we show the performance of different LTFU time periods in 7-day increments.

^b The best-performing definition of LTFU coincided with the 56-day intervals.


60 jours = définition opérationnelle

Chi et al. (2010), An Empirical Approach to Defining Loss to Follow-up Among Patients Enrolled in Antiretroviral Treatment Programs, *American Journal of Epidemiology*, 171:924–931


- 9308 visites pour lesquelles une date de rendez-vous avait été donnée
 - 2893 (31 %) ont eu lieu à cette date



Lissage des retards




Vitesse de retour des retards





Définition - conclusion

- Définition OMS : 90 jours
- 60 jours paraît plus opérationnel
- 15 jours paraît un bon délai d'alerte précoce

MESURE







Mortality of Patients Lost to Follow-Up in Antiretroviral Treatment Programmes in Resource-Limited Settings: Systematic Review and Meta-Analysis

Martin W. G. Brinkhof^{1*}, Mar Pujades-Rodriguez^{1,2}, Matthias Egger^{1,3}

1 Division of International and Environmental Health, Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland, **2** Epicentre, Médecins Sans Frontières, Paris, France, **3** Department of Social Medicine, University of Bristol, Bristol, United Kingdom

Table 2. Vital status of patients lost to follow up in ART programmes in resource-limited settings.

Study	Number of patients		Vital status of patients lost to follow-up (%)			Mortality among traced
	LTFU	Included (%)	Unknown (n)	Alive (n)	Dead (n)	
Articles						
Yu 2007	253	253 (100%)	27% (68)	23% (58)	50% (127)	69%
Maskew 2007	154	154 (100%)	55% (84)	33% (51)	12% (19)	27%
Dalal 2008	267	267 (100%)	35% (94)	34% (90)	31% (83)	48%
Krebs 2008 [#]	n.r.	1343 (-)	41% (554)	32% (430)	27% (359)	46%
Bisson 2008	68	68 (100%)	32% (22)	9% (6)	59% (40)	87%
Geng 2008	829	128 (15%)	13% (17)	62% (79)	25% (32)	29%
Deribe 2008	355	355 (100%)	18% (65)	61% (215)	21% (75)	27%
An 2008 [#]	3528	1143 (32%)	46% (522)	43% (497)	11% (124)	20%
Conference abstracts						
Ive 2005	n.r.	74 (-)	35% (26)	30% (22)	35% (26)	54%
Hochgesang 2006	1843	727 (39%)	26% (189)	44% (320)	30% (218)	41%
Billy 2007	273	113 (41%)	14% (16)	55% (62)	31% (35)	36%
Dahab 2008	44	44 (100%)	20% (9)	39% (17)	41% (18)	51%
Dahab 2008 [‡]	53	53 (100%)	23% (12)	68% (36)	9% (5)	12%
Lurton 2008	236	61 (26%)	16% (10)	43% (26)	41% (25)	49%
Joshi 2008 [‡]	152	152 (100%)	30% (46)	61% (93)	9% (13)	12%
Muwanga 2008	831	831 (100%)	55% (459)	26% (213)	19% (159)	43%
McGuire 2009	1233	654 (53%)	32% (206)	31% (204)	37% (244)	54%
Overall		6420 (100%)	37%	38%	25%	40%
Patients on ART (excluding [#])		3934	34%	38%	28%	42%
On ART, Africa, public programme, (excluding ^{#, ‡})		3729	34%	37%	29%	46%

EXPLICATION

Résultats des études effectuées

- Reprise d'IMC / sentiment de guérison
- Statut matrimonial / Evolution de ce statut
- Éléments liés à la prise en charge

- La distance n'apparaît pas comme un facteur de perte de vue.

Remerciement aux associations de patients et aux travailleurs sociaux impliqués dans ces études


PERSPECTIVES

Élargissement de la réflexion

Les PDV dans la PTME

- Définition : quelle unité ?
- Mesure : opérationnalité des outils en place?
- Explication : facteurs spécifiques ?

Approfondir la compréhension des PDV



Remerciements

Le comité thérapeutique de la région de Ségou

Les ONG Wale et Aprofem

Association Badeyaton, Keneyaton

Les autorités sanitaires de la région de Ségou

Institut Pasteur (Y. Madec)